Zacks: Analysts Expect Agile Therapeutics Inc (AGRX) Will Announce Earnings of -$0.11 Per Share
Wall Street brokerages expect Agile Therapeutics Inc (NASDAQ:AGRX) to announce ($0.11) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have made estimates for Agile Therapeutics’ earnings, with estimates ranging from ($0.13) to ($0.10). Agile Therapeutics posted earnings per share of ($0.21) during the same quarter last year, which indicates a positive year-over-year growth rate of 47.6%. The company is expected to report its next quarterly earnings results on Monday, May 6th.
According to Zacks, analysts expect that Agile Therapeutics will report full year earnings of ($0.55) per share for the current financial year, with EPS estimates ranging from ($0.66) to ($0.34). For the next financial year, analysts expect that the business will report earnings of ($0.48) per share, with EPS estimates ranging from ($0.79) to $0.11. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Agile Therapeutics.
Agile Therapeutics (NASDAQ:AGRX) last announced its quarterly earnings data on Tuesday, March 12th. The specialty pharmaceutical company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.04.
Shares of AGRX opened at $1.61 on Tuesday. The firm has a market cap of $57.41 million, a PE ratio of -2.78 and a beta of 0.36. Agile Therapeutics has a 1-year low of $0.23 and a 1-year high of $3.24.
Several institutional investors and hedge funds have recently made changes to their positions in AGRX. BlackRock Inc. lifted its position in Agile Therapeutics by 15.7% during the fourth quarter. BlackRock Inc. now owns 133,219 shares of the specialty pharmaceutical company’s stock valued at $77,000 after purchasing an additional 18,038 shares during the period. Geode Capital Management LLC lifted its position in Agile Therapeutics by 24.0% during the fourth quarter. Geode Capital Management LLC now owns 230,496 shares of the specialty pharmaceutical company’s stock valued at $132,000 after purchasing an additional 44,639 shares during the period. Acadian Asset Management LLC lifted its position in Agile Therapeutics by 260.7% during the fourth quarter. Acadian Asset Management LLC now owns 313,047 shares of the specialty pharmaceutical company’s stock valued at $180,000 after purchasing an additional 226,255 shares during the period. Fosun International Ltd acquired a new position in Agile Therapeutics during the third quarter valued at $180,000. Finally, Renaissance Technologies LLC lifted its position in Agile Therapeutics by 54.3% during the third quarter. Renaissance Technologies LLC now owns 1,223,897 shares of the specialty pharmaceutical company’s stock valued at $449,000 after purchasing an additional 430,907 shares during the period. 42.15% of the stock is currently owned by hedge funds and other institutional investors.
Agile Therapeutics Company Profile
Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.
Read More: Asset Allocation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.